NCT07339332 is a EARLY_PHASE1 clinical trial of CAR-T Therapy in Systemic Lupus Erythematosus (SLE), sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.

What drugs are being tested in NCT07339332?

Interventions in NCT07339332: CAR-T Therapy.

What condition does NCT07339332 study?

NCT07339332 studies Systemic Lupus Erythematosus (SLE).

Is NCT07339332 still recruiting?

NCT07339332 is currently recruiting now. Last updated 14 January 2026.

Last reviewed 2026-01-14 · How we verify

NCT07339332

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Dynamics of Universal CD19 / 20 Car-t Cell Injection in Moderate to Severe Refractory Systemic Lupus Erythematosus

Recruiting now EARLY_PHASE1 Last updated 14 January 2026

What this trial tests

EARLY_PHASE1 trial testing CAR-T Therapy in Systemic Lupus Erythematosus (SLE) in 12 participants. Currently enrolling.

Timeline

16 January 2026

Primary endpoint
30 June 2027

31 December 2027

Quick facts

Lead sponsor	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase	EARLY_PHASE1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	16 January 2026
Primary completion	30 June 2027
Estimated completion	31 December 2027
Sites	1 location across China

Drugs / interventions tested

CAR-T Therapy — full drug profile →

Conditions studied

Systemic Lupus Erythematosus (SLE) — all drugs for Systemic Lupus Erythematosus (SLE) →

Sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Who can join

Adults 18 to 65, any sex, with Systemic Lupus Erythematosus (SLE). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a single arm, open, exploratory dose escalation clinical study to evaluate the safety, efficacy, and cellular metabolic dynamics of ct1195e cells in patients with SLE.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of CAR-T Therapy

Trials testing the same drug.

NCT07355972 — Safety, Efficacy and Cellular Metabolic Dynamics of CT1195E in Patients With Refractory / Progressive SSC · EARLY_PHASE1 · recruiting
NCT07280494 — To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCT · Phase 1 · recruiting
NCT07051850 — Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies · recruiting
NCT07031713 — Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE · Phase 1 · recruiting
NCT07033299 — The Safety, Efficacy, and Cellular Metabolic Kinetics of CT1192 in Treating Patients With Anti Neutrophil Cytoplasmic An · Phase 1 · not yet recruiting

Other recruiting trials for Systemic Lupus Erythematosus (SLE)

Currently open trials in the same condition.

NCT07447986 — To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus · Phase 2 · recruiting
NCT07490041 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refr · EARLY_PHASE1 · recruiting
NCT07087912 — Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases · Phase 4 · recruiting
NCT07332481 — A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease · Phase 3 · recruiting
NCT06875960 — A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Dis · Phase 4 · recruiting

Other Union Hospital, Tongji Medical College, Huazhong University of Science and Technology trials

Trials by the same sponsor.

NCT07521124 — ABC Maintenance Therapy for AML · NA · not yet recruiting
NCT07497243 — X-ray Assisted Diagnostic System · not yet recruiting
NCT07520123 — Union-FAST: An Intelligent-Agent Intervention to Increase Antiviral Treatment Uptake in Diagnosed-but-Untreated Hepatiti · NA · not yet recruiting
NCT06970262 — FMT for Lung and Associated-organ Rescue Efficacy in ARDS Patients · NA · recruiting
NCT07509424 — Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Lo · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07339332 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Last refreshed: 14 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07339332.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing